ArticleFrontiers in immunology2026
Tocilizumab-induced inflammatory flare in Takayasu arteritis: a case report with exploratory mechanistic findings of Fcγ receptor involvement.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To report a refractory Takayasu arteritis (TAK) patient who developed a severe inflammatory flare after tocilizumab (TCZ) therapy and explore the underlying mechanism. Case presentation: A 21-year-old female with active TAK received TCZ after insufficient response to prednisone. TCZ was temporarily withheld then re-added at 400 mg due to disease relapse. After TCZ reintroduction, the patient developed worsening vascular pain, new abdominal pain, dizziness, fever, and markedly elevated inflammatory markers. Imaging showed worsened arteritis and new superior mesenteric arteritis. Methylprednisolone pulse and infliximab failed to control the flare, but tofacitinib achieved complete symptom resolution and normalized inflammatory markers within one month. In vitro findings: Peripheral blood samples of the patient were collected and peripheral blood mononuclear cells (PBMCs) Fcγ receptor (FcγR) expression and downstream signaling were assessed upon TCZ stimulation. Conclusion: TCZ can paradoxically trigger an inflammatory flare in refractory TAK, with exploratory evidence suggesting possible involvement of excessive FcγR activation. Non-antibody-based Janus kinase (JAK) inhibitors like tofacitinib may be effective rescue therapy in such cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.